You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Myeloablative Autologous Gene Therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Trial in Minneapolis (Thiotepa, Cyclophosphamide, Melphalan)

Recruiting
  • Neuroblastoma
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 2, 2022

Sickle Cell Disease Trial in Paris (DREPAGLOBE drug product)

Active, not recruiting
  • Sickle Cell Disease
  • DREPAGLOBE drug product
  • Paris, France
    Department of Biotherapy, Necker-Enfants Malades Hospital
Sep 26, 2022

Gaucher Disease, Type 3 Trial (Gene therapy, Enzyme Replacement Agent)

Not yet recruiting
  • Gaucher Disease, Type 3
  • Gene therapy
  • Enzyme Replacement Agent
  • (no location specified)
Apr 14, 2023

Hepatocellular Carcinoma Trial in Beijing (iNKT Cells, PD-1, Regorafenib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • iNKT Cells
  • +2 more
  • Beijing, Beijing, China
    Beijing Youan Hospital,Capital Medical University
Jul 24, 2023

Wiskott-Aldrich Syndrome Trial in Atlanta, Milan (OTL-103)

Active, not recruiting
  • Wiskott-Aldrich Syndrome
  • OTL-103
  • Atlanta, Georgia
  • +1 more
Sep 27, 2022

Cerebral Adrenoleukodystrophy (CALD) Trial in Worldwide (Lenti-D)

Active, not recruiting
  • Cerebral Adrenoleukodystrophy (CALD)
  • Lenti-D
  • Palo Alto, California
  • +7 more
Mar 22, 2022

Patients Previously Treated With Autologous ex Vivo Gene Therapy

Enrolling by invitation
  • Adenosine Deaminase Deficiency
  • Severe Combined Immunodeficiency (SCID)
  • autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
  • Los Angeles, California
  • +1 more
Mar 31, 2022

Leukocyte Adhesion Defect - Type I Trial in Madrid (RP-L201)

Withdrawn
  • Leukocyte Adhesion Defect - Type I
  • RP-L201
  • Madrid, Spain
    Hospital Infantil Universitario Niño Jesús (HIUNJ)
Nov 23, 2021

Endocrine/Neuroendocrine, NSCLC, Breast Cancer Trial run by the National Cancer Institute (NCI) (Fludarabine, Cyclophosphamide,

Recruiting
  • Endocrine/Neuroendocrine
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 24, 2022

Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Neuroblastoma
  • GINAKIT Cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Jan 18, 2023

Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency Trial in Paris (ARTEGENE drug product)

Not yet recruiting
  • Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
  • ARTEGENE drug product
  • Paris, France
    Department of Pediatric Immunology, Hematology and Rheumatology
Sep 26, 2022

Fabry Disease Who Received Lentiviral Gene Therapy in Study

Enrolling by invitation
  • Fabry Disease
  • Safety and Efficacy Assessments
  • Melbourne, Parkville VIC, Australia
  • +2 more
Oct 5, 2022

Transfusion Dependent Beta-Thalassemia Trial in Nanning (GMCN-508B (LentiRed))

Recruiting
  • Transfusion Dependent Beta-Thalassemia
  • GMCN-508B (LentiRed)
  • Nanning, Guangxi, China
    The affiliated hospital of guangxi medical university
Feb 28, 2023

Sickle Cell Disease Trial in United States (bb1111)

Recruiting
  • Sickle Cell Disease
  • bb1111
  • Birmingham, Alabama
  • +8 more
Jul 15, 2022

Metachromatic Leukodystrophy, Adrenoleukodystrophy Trial in Shenzhen (transduced CD34+ hematopoietic stem cell)

Recruiting
  • Metachromatic Leukodystrophy
  • Adrenoleukodystrophy
  • transduced CD34+ hematopoietic stem cell
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital, The First Affiliated Hospital
May 25, 2022

Pleural Mesothelioma Trial in Toronto (Cyclophosphamide, Fludarabine, Autologous tumor infiltrating lymphocytes (TILs))

Completed
  • Pleural Mesothelioma
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Transfusion-dependent a-Thalassemia Trial (GMCN-508A Drug Product)

Not yet recruiting
  • Transfusion-dependent α-Thalassemia
  • GMCN-508A Drug Product
  • (no location specified)
Feb 24, 2023

Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial in Zhengzhou (ThisCART19A, Fludarabine Pill, Cyclophosphamide)

Not yet recruiting
  • Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
  • Zhengzhou, Henan, China
    Henan cancer hospital
Nov 28, 2022

Sexual Dysfunction Female Trial in Hanoi (Autologous adipose-derived mesenchymal stem cell administration for female with sexual

Not yet recruiting
  • Sexual Dysfunction Female
  • Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency
  • Hanoi, Vietnam
    Vinmec Research Institute of Stem Cell and Gene Technology
Aug 23, 2022

Severe Combined Immunodeficiency Trial in San Francisco (AProArt, CliniMACS® CD34 Reagent System cell sorter device, Busulfan)

Recruiting
  • Severe Combined Immunodeficiency
  • San Francisco, California
    University of California, San Francisco (UCSF) Children's Hospit
Feb 4, 2022

Patients With Premature Ovarian Failure ex Vivo Gene Therapy

Active, not recruiting
  • Primary Ovarian Insufficiency
  • Premature Ovarian Failure
  • Observational
  • Kharkov, Ukraine
    Institute of Bio-Stem Cell Rehabilitation
May 16, 2022

Epidermolysis Bullosa Dystrophica, Recessive Trial in Paris (COL7A1-SIN retroviral vector engineered autologous

Active, not recruiting
  • Epidermolysis Bullosa Dystrophica, Recessive
  • COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin
  • Paris, France
    Institut Imagine Necker Hospital
Oct 18, 2021

Liver Cell Carcinoma Trial in Houston (CATCH T cells, Cytoxan, Fludara)

Recruiting
  • Liver Cell Carcinoma
  • +7 more
  • CATCH T cells
  • +2 more
  • Houston, Texas
    Houston Methodist Hospital
Dec 19, 2022

Sarcoma Trial in Houston (Autologous HER2-specific T cells, Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Sarcoma
  • Autologous HER2-specific T cells
  • +3 more
  • Houston, Texas
  • +1 more
Nov 21, 2022

Severe Combined Immunodeficiency Due to RAG1 Deficiency Trial in Leiden (Gene therapy)

Recruiting
  • Severe Combined Immunodeficiency Due to RAG1 Deficiency
  • Gene therapy
  • Leiden, Netherlands
    Leiden University Medical Center
Dec 3, 2021